Low Dose Naltrexone

Low Dose Naltrexone

Naltrexone is part of a large class of drugs known as opiate antagonists. In high dosages (usually between 50 and 300mg daily), Naltrexone can be used to treat addiction to opioids such as heroin or morphine by blocking the effect of these drugs on the brain. In other words, Naltrexone reduces the “high” associated with opiate drugs.

At significantly lower dosages, however, Naltrexone has been shown to moderate the symptoms of numerous chronic medical conditions, as well as help minimize chronic pain associated with cancer and other diseases. Low Dose Naltrexone—the same drug at significantly lower dosages, usually no more than 5mg—is believed to operate as an anti-inflammatory agent on the central nervous system, and has been shown to have a mitigating impact even on diseases not specifically associated with inflammation.

For patients suffering from chronic conditions associated with discomfort and pain, daily dosages of LDN are generally considered to be safe, well-tolerated with a minimum of side effects, and relatively inexpensive. Naltrexone has been FDA approved in higher doses (50mg) for the treatment of opioid addiction since 1984. While the use of significantly lower dosages of Naltrexone (LND) has not specifically been approved by the FDA because the drug has passed all animal toxicity testing and therefore the off-label use of this drug is both ethical and legal.

LDN has been found to have a significant ameliorating impact on the symptoms of a wide range of diseases and medical conditions, so many, in fact, that it is impossible to name them all here. However, all of the conditions for which LDN may be appropriate share a common feature: the involvement of the immune symptom, including low blood levels of endorphins. The one exception to this is certain types of cancers, in which it seems that LDN has an impact on opioid receptors found in some tumors.

Generally speaking, the conditions for which your physician may prescribe LDN can be grouped in the following categories:

  • Autoimmune diseases such as Crohn’s disease, fibromyalgia, multiple sclerosis, and lupus
  • HIV/AIDS
  • Central nervous system disorders such as Parkinson’s disease, Alzheimer’s disease, ALS (Lou Gehrig’s disease), and primary lateral sclerosis
  • Psychological disorders
  • Cancer, specifically brain tumors, breast cancer, squamous cell carcinoma, myeloid leukemia, lung cancer, and neuroblastoma
  • Hashimoto’s Disease

This list is by no means comprehensive, however. LDN is increasingly being recognized for its positive impact on many different medical concerns, and your physician may have prescribed it as a potential benefit for your specific condition even if it is not on this limited list.

Formulation Compounding Center Affiliated Partners

National Community Pharmacists Association
MEDISCA Your Trusted Partner In Compounding
Fagron
PCCA